Male-GBG54 : a prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen plus /- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor plus GnRHa in male breast cancer patients

Reinisch, M.; Strittmatter, Hj.; Strik, D.; Loibl, S.; Seiler, S.; Furlanetto, J.; Zahm, D. M.; Schmatloch, S.; Kamischke, A.; Rudlowski, C.; Marme, F.; Hauzenberger, T.; Nekljudova, V.; Janni, W.; Jackisch, C.; Thode, C.; Schmidt, M.; von Minckwitz, G.; Stickeler, Elmar

doi:0008-5472

Mehr Informationen
Referenzen (0)
Diskussion (0)
Dateien

Male-GBG54 : a prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen plus /- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor plus GnRHa in male breast cancer patients - RWTH-2018-222712

Ähnliche Datensätze

h1

h2

h3

h4

h5

h6

RWTH

Kontakt

RWTH Publications

Allgemeines